Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy.
about
r84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity inductionAntibody drug-conjugates targeting the tumor vasculature: Current and future developmentsA review of the past, present, and future directions of neoplasiaComing of Age in the Life ofPhosphorylation of Akt and ERK1/2 is required for VEGF-A/VEGFR2-induced proliferation and migration of lymphatic endotheliumCytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer.Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma.Novel small peptides derived from VEGF125-136: potential drugs for radioactive diagnosis and therapy in A549 tumor-bearing nude mice.Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in miceThe vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors.Identification of a Monoclonal Antibody That Attenuates Antiphospholipid Syndrome-Related Pregnancy Complications and Thrombosis.Virion-associated phosphatidylethanolamine promotes TIM1-mediated infection by Ebola, dengue, and West Nile viruses.Targeted microbubbles for imaging tumor angiogenesis: assessment of whole-body biodistribution with dynamic micro-PET in mice.Decorin is a novel VEGFR-2-binding antagonist for the human extravillous trophoblastVisualization of tumor angiogenesis using MR imaging contrast agent Gd-DTPA-anti-VEGF receptor 2 antibody conjugate in a mouse tumor model.Vascular Repair by Tissue-Resident Endothelial Progenitor Cells in Endotoxin-Induced Lung Injury.Targeted molecular imaging of VEGF receptors overexpressed in ischemic microvasculature using chitosan-DC101 conjugates.The patterns and expression of KDR in normal tissues of human internal organs.VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells.Plasma Protein β-2-Glycoprotein 1 Mediates Interaction between the Anti-tumor Monoclonal Antibody 3G4 and Anionic Phospholipids on Endothelial Cells
P2860
Q27321768-5C669D6A-B0EC-457F-B9C0-97800473BDA7Q28270261-D4C0EBE4-0C11-4ADC-8D23-10D21D5FB21EQ28389391-B734EC27-23ED-48E5-BED3-5D4E4F831BDDQ28389985-064EA883-DFFF-461F-BCFC-9D8950919C34Q28741586-EC5F1A22-D65E-4ECD-B500-90875EC8BB51Q33514852-87307745-2EA5-49B7-83B6-8294127E0E3AQ33592374-0197F8ED-1719-4E3B-BA16-228335329A68Q33842838-420DC292-56D1-4547-8E62-DB49E79439A2Q33995228-9039FE8C-9E54-4AF6-9366-918F2683895BQ34245416-93C048E1-A3AF-4C0D-BFDA-EBDC7ACF97C0Q34768492-399DD5F0-AAB9-4D2C-9C8D-74A6718F0DD4Q36087118-5A65418B-A873-4A66-830A-3CDD026EBD0BQ36332001-764BB674-2733-46C0-BDEA-E133AF4DCB25Q37133833-82DB0502-F311-47D7-A15B-9D48758A32E8Q39527514-0802955A-AAD2-4AED-8CC9-498D29476BB7Q41510549-BB5FBBD7-04D7-42F2-8564-177A6D9D81EDQ46767334-457802A5-67EB-420A-BC13-54C91EB3B67DQ47854441-ACF8147B-292B-454C-BDDF-ECFEE856F627Q48905409-9EBFFBBA-F1EA-4B68-AF3B-D7AAE68FD40BQ54539963-C1F519BB-1960-4732-84D9-23E198EE8146Q57372547-AC38897D-4FDD-46A6-B690-26AB70ABF416
P2860
Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Evaluation of novel antimouse ...... ting agents for tumor therapy.
@ast
Evaluation of novel antimouse ...... ting agents for tumor therapy.
@en
Evaluation of novel antimouse ...... ting agents for tumor therapy.
@nl
type
label
Evaluation of novel antimouse ...... ting agents for tumor therapy.
@ast
Evaluation of novel antimouse ...... ting agents for tumor therapy.
@en
Evaluation of novel antimouse ...... ting agents for tumor therapy.
@nl
prefLabel
Evaluation of novel antimouse ...... ting agents for tumor therapy.
@ast
Evaluation of novel antimouse ...... ting agents for tumor therapy.
@en
Evaluation of novel antimouse ...... ting agents for tumor therapy.
@nl
P2093
P2860
P1433
P1476
Evaluation of novel antimouse ...... ting agents for tumor therapy.
@en
P2093
Amber Downes
Philip E Thorpe
Sophia Ran
Xianming Huang
P2860
P304
P356
10.1016/S1476-5586(03)80023-4
P577
2003-07-01T00:00:00Z